InterCure announced today that it has entered into a definitive Share Purchase Agreement and a Collaboration Agreement with Cannasoul R&D Ltd. The agreement gives InterCure a 28% stake in Cannasoul, with an exclusive path to increase its holdings to 51% within two years, providing the company with immediate access to Cannasoul’s advanced analytics and research capabilities.
The collaboration will combine InterCure’s pharmaceutical‑grade platform with Cannasoul’s world‑class analytics and scientific innovation. The partnership is expected to accelerate the development of evidence‑based cannabis therapeutics and expand InterCure’s international footprint. The appointment of Cannasoul founder Prof. Dedi Meiri as Chairperson of InterCure’s Scientific Advisory Board will further integrate the two companies’ research efforts.
The deal is strategically timed as the U.S. cannabis market faces a potential regulatory shift, with the Trump administration reportedly exploring rescheduling cannabis from Schedule I to Schedule III. By securing a stake in Cannasoul, InterCure positions itself to capitalize on the anticipated U.S. market opening and strengthens its scientific leadership in the global cannabis space.
The acquisition is expected to be accretive to InterCure’s business within the first year, providing a stronger foundation for future growth in Israel, Europe, and potentially the United States. The partnership underscores InterCure’s commitment to expanding its research capabilities and leveraging advanced analytics to drive product innovation.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.